Sonoma Pharmaceuticals, Inc.
SNOA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SNOA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SNOA
Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing stabilized hypochlorous acid (HOCl) products for wound care, dermatology, and eye care, with a market cap of approximately $5.3 million as of its latest financial report.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for Sonoma Pharmaceuticals, Inc..
Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing stabilized hypochlorous acid (HOCl) products for wound care, dermatology, and eye care, with a market cap of approximately $5.3 million as of its latest financial report.
- Cash and equivalents of $5.3 million as of 2026-06-30 [sec].
- Total revenue of $6.4 million for the trailing twelve months as of 2026-06-30 [sec].
- Net loss of $0.3 million for the trailing twelve months as of 2026-06-30 [sec].
- Shareholders' equity of $3.1 million as of 2026-06-30 [sec].
- Total debt of $0.1 million as of 2026-06-30 [sec].
What works
- The company has a low debt level of $0.1 million as of 2026-06-30, indicating minimal leverage risk [sec].
- Revenue of $6.4 million demonstrates existing commercial traction for its HOCl-based products [sec].
- The company has access to additional capital resources, including public or private equity offerings and debt financings, to support strategic initiatives [sec_mda · as of 2026-06-16].
What to weigh
- The company has a history of losses, and there is substantial doubt about its ability to continue as a going concern [sec_mda · as of 2025-11-04].
- The company depends on third-party distributors, which introduces execution risk [sec_mda · as of 2026-02-10].
- The company faces risks related to regulatory approvals, clinical data sufficiency, and intellectual property protection [sec · filed 2025-04-28].
- Cash of $5.3 million may be insufficient to fund operations without additional financing, and there is no assurance that such financing will be available on acceptable terms [sec_mda · as of 2026-06-16].
From the filings
Quoted directly from source documents.
Substantial doubt about going concern due to history of losses
“This uncertainty along with the our history of losses indicates that there is substantial doubt about the our ability to continue as a going concer”
SEC MD&A · November 4, 2025
Dependence on third-party distributors
“our dependence on third-party distributors”
SEC MD&A · February 10, 2026
Access to additional capital resources
“We also have access to additional capital resources, which may include public or private equity offerings, debt financings, corporate collaborations, or other means, if and when appropriate to support strategic initiatives.”
SEC MD&A · June 16, 2026
Risk that clinical results may not be replicated
“clinical results may not be replicated in actual patient settings”
SEC filings · January 12, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — History of losses and cash constraints raise substantial doubt about ability to continue as a going concern [sec_mda · as of 2025-11-04].
- Dependence on third-party distributors — Revenue generation relies on third-party distributors, which may affect market penetration and margins [sec_mda · as of 2026-02-10].
- Regulatory and clinical risks — Products require FDA and other regulatory approvals; clinical data may not meet standards [sec · filed 2025-04-28].
- Capital raising risk — No assurance that additional financing will be available on acceptable terms if needed [sec_mda · as of 2026-06-16].
What to watch
- Ability to secure additional financing to extend cash runway beyond the next twelve months [sec_mda · as of 2026-06-16].
- Progress in transitioning European products to the new Medical Device Regulation [sec_mda · as of 2026-02-10].
- Outcome of discussions with the FDA and other regulatory agencies regarding product approvals [sec_mda · as of 2026-08-06].
- Revenue growth trajectory and ability to achieve profitability [sec_mda · as of 2026-02-10].
Sources: News · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Sonoma Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Sonoma Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
39.8 months
D/E 1.75 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$131K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 37,574 | $80K |
| geode capital management, llc | 19,941 | $42K |
| morgan stanley | 2,004 | $4K |
| citigroup inc | 1,425 | $3K |
| osaic holdings, inc. | 500 | $1K |
| blackrock, inc. | 113 | $241 |
| vanguard fiduciary trust co | 100 | $213 |
| us bancorp \de\ | 25 | $53 |
| ubs group ag | 6 | $13 |
| quaker wealth management, llc | 3 | $7 |
Showing top 10 of 13 institutional holders of Sonoma Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 21.7%
- Days to cover
- 2.1
- Shares short
- 751,721
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SNOA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Sonoma Pharmaceuticals, Inc.?
Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing stabilized hypochlorous acid (HOCl) products for wound care, dermatology, and eye care, with a market cap of approximately $5.3 million as of its latest financial report.
Who is the CEO of Sonoma Pharmaceuticals, Inc.?
Ms. Amy M. Trombly Esq., J.D. is the chief executive officer of Sonoma Pharmaceuticals, Inc. (SNOA).
Where is Sonoma Pharmaceuticals, Inc. headquartered?
Sonoma Pharmaceuticals, Inc. (SNOA) is headquartered in Boulder, CO, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.